FDA Approves Pimicotinib for Rare Soft-Tissue Tumor Treatment
New oral inhibitor offers therapeutic option for patients with unresectable tenosynovial giant cell tumors.
1Regulatory Approval Milestone
The FDA recently approved pimicotinib, marketed as Pimjetmi, for patients diagnosed with symptomatic tenosynovial giant cell tumor. This small-molecule inhibitor is specifically indicated for individuals facing high surgical risks or potential functional decline. It represents the third therapeutic option approved for this rare condition, following previous entries in 2019 and 2025.
2Understanding the Condition
Tenosynovial giant cell tumor is a rare, locally aggressive soft-tissue condition primarily affecting younger adults with a median age of 38. The disease originates in joint synovium, bursae, or tendon sheaths. It often causes substantial functional limitations, making surgical intervention the primary treatment choice when the tumor remains physically accessible.
3Clinical Trial Evidence
Approval was primarily supported by the phase III MANEUVER trial, which randomized 94 patients across Asia, Europe, and North America. Participants received either pimicotinib or a placebo in a 2:1 ratio. The study successfully met its primary endpoint of objective response rate at week 25, showing significant efficacy over the placebo group.
4Efficacy and Response Rates
The primary analysis revealed an objective response rate of 54% for patients treated with pimicotinib, compared to only 3% in the placebo group. Recent two-year follow-up data indicates durable responses in 76-78% of patients. These results also demonstrate consistent improvements in patient-reported outcomes, including reduced pain, decreased stiffness, and better range of motion.
5Patient Functional Impact
Investigator Vinod Ravi noted that the disease significantly impacts mobility and the ability to perform everyday activities. The consistency of improvements observed over two years suggests that pimicotinib provides meaningful long-term benefits. These findings are particularly encouraging for patients who previously lacked effective, non-surgical options to manage their persistent physical limitations.
6Safety and Side Effects
Common adverse reactions reported in at least 20% of patients included pruritus, rash, and facial or periorbital edema. Other frequent side effects were fatigue, nausea, headache, and peripheral edema. Clinicians should monitor patients for these symptoms, as the safety profile remains a critical consideration for long-term administration of this oral inhibitor.
7Laboratory Monitoring Requirements
Laboratory abnormalities occurred in more than 30% of patients during the clinical trial process. Notable markers included increased levels of creatine phosphokinase, lactate dehydrogenase, and aspartate aminotransferase. Additionally, clinicians observed elevated lipase, cholesterol, amylase, and alanine aminotransferase levels, necessitating regular blood work to ensure patient safety throughout the course of treatment.
8Global Market Context
Beyond its recent FDA approval, pimicotinib has already received regulatory clearance in other international markets. The drug was approved in China earlier in 2025, as well as in Canada and Switzerland. This global rollout highlights the drug's expanding role in treating rare, locally aggressive soft-tissue tumors that require specialized medical intervention.
Original article: MedPage Today — FDA Approves Pimicotinib for Rare Soft-Tissue Tumor Treatment